June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Effects of Intravitreal Ranibizumab on Diabetic Retinopathy Severity: 36 Month Data from the RISE and RIDE Phase III Trials
Author Affiliations & Notes
  • Jason Ehrlich
    Genentech, Inc, South San Francisco, CA
  • Amitha Domalpally
    Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, WI
  • Linda Yau
    Genentech, Inc, South San Francisco, CA
  • J Hopkins
    Genentech, Inc, South San Francisco, CA
  • Michael Ip
    Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, WI
  • Footnotes
    Commercial Relationships Jason Ehrlich, Genentech (E), Roche (I); Amitha Domalpally, None; Linda Yau, Genentech, Inc. (E); J Hopkins, Genentech, Inc. (E); Michael Ip, Eye Technology Ltd. (C), Genentech, Inc. (C), NicOx (C), Notal Vision (C), QLT Phototherapeutics, Inc. (C), Regeneron (C), Sirion (C), Allergan, Inc (F), Regeneron (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4028. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jason Ehrlich, Amitha Domalpally, Linda Yau, J Hopkins, Michael Ip; Effects of Intravitreal Ranibizumab on Diabetic Retinopathy Severity: 36 Month Data from the RISE and RIDE Phase III Trials. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4028. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To assess the effect of intravitreal ranibizumab on diabetic retinopathy (DR) severity.

 
Methods
 

Exploratory analysis in participants with diabetic macula edema (DME) meeting eligibility criteria (n=759) including best corrected visual acuity of 20/40 to 20/320 Snellen equivalent and OCT central subfield thickness of ≥275 μm, were randomized 1:1:1 to receive monthly 0.3 mg or 0.5 mg ranibizumab, or sham injections. Sham participants were eligible to receive 0.5 mg ranibizumab during the third year. All participants were eligible for macular laser beginning at Month 3, and panretinal photocoagulation (PRP) was available as needed. Fundus photographs, taken at baseline and pre-specified intervals, were graded by a central reading center; clinical examinations were performed monthly. Analysis outcomes included: ≥2, ≥3-step change on the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale in the study eye; and a composite clinical progression outcome including photographic changes plus clinically-important events such as occurrence of vitreous hemorrhage or application of PRP. Time to first DR progression was analyzed by Kaplan-Meier methods to calculate cumulative probabilities by treatment group.

 
Results
 

A greater proportion of eyes in the ranibizumab arms had a ≥2- or ≥3-step DR regression (improvement) on the ETDRS severity scale compared to eyes in the sham/0.5 mg crossover group at month 36. A ≥3-step improvement was achieved at 36 months by 3.3%, 15.0% and 13.2% of the sham/0.5 mg crossover, 0.3 mg and 0.5 mg ranibizumab treated eyes, respectively. Through 36 months 33.9% of eyes originally randomized to sham developed proliferative DR (PDR) as measured by the composite outcome, compared to 12.8% and 15.1 % of 0.3 mg and 0.5 mg ranibizumab-treated eyes respectively, although the proportions of participants exhibiting DR progression during the third year were similar in all three arms.

 
Conclusions
 

These data, derived from two large randomized, controlled trials of ranibizumab for DME, provide strong evidence that ranibizumab is effective in reducing DR severity and can inhibit clinical progression to PDR evaluated by composite outcomes. However, prolonged delays in initiation of ranibizumab therapy, as in the RIDE/RISE sham group, may limit this therapeutic effect.

 
Keywords: 499 diabetic retinopathy • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×